

# CITATION REPORT

List of articles citing

## Olmesartan-associated enteropathy: results of a national survey

DOI: 10.1111/apt.12937

Alimentary Pharmacology and Therapeutics, 2014, 40, 1103-9

**Source:** <https://exaly.com/paper-pdf/58269204/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
156	Irbesartan/olmesartan medoxomil. <b>2014</b> , 1527, 129-129		
155	Editorial: sprue-like enteropathy due to olmesartan and other angiotensin receptor blockers--the plot thickens. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 40, 1245-6	6.1	5
154	Sprue-like enteropathy associated with olmesartan - broadening the differential diagnosis of enteropathy. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2014</b> , 40, 1362-3	6.1	9
153	A Case of Severe Sprue-like Enteropathy Associated With Losartan. <b>2015</b> , 49, 794		18
152	Refraktõe Zõakie. <b>2015</b> , 10, 492-497		2
151	Immunopathogenesis of olmesartan-associated enteropathy. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2015</b> , 42, 1303-14	6.1	35
150	Olmesartan-Associated Enteropathy: A Review of Clinical and Histologic Findings. <b>2015</b> , 139, 1242-7		41
149	Gastrointestinal Disorder Associated with Olmesartan Mimics Autoimmune Enteropathy. <b>2015</b> , 10, e0125024		44
148	Blockers of Angiotensin Other Than Olmesartan in Patients With Villous Atrophy: A Nationwide Case-Control Study. <b>2015</b> , 90, 730-7		11
147	Clinical-Pathological Conference Series from the Medical University of Graz: Case No 156: 82-year-old woman with chronic diarrhea and weight loss of 20 kilograms. <b>2015</b> , 127, 974-80		4
146	Identification of new cases of severe enteropathy has recently increased the spectrum of intestinal non-celiac villous atrophy. <b>2015</b> , 9, 719-21		8
145	Drug-induced enteropathy. <b>2015</b> , 33, 215-220		24
144	Adaptive diagnosis of coeliac disease. <b>2015</b> , 29, 381-98		18
143	Could HLA-DQ suggest why some patients have olmesartan-related diarrhea and others don't?. <b>2015</b> , 110, 1507-8		8
142	Adding Water to the Mill: Olmesartan-Induced Collagenous Sprue-A Case Report and Brief Literature Review. <b>2016</b> , 2016, 4837270		9
141	Duodenal Villous Atrophy in a TTG-Negative Patient Taking Olmesartan: A Case Report and Review of the Literature. <b>2016</b> , 2016, 6091571		6
140	Olmesartan-induced Enteropathy Manifesting as Wernicke-Korsakoff Syndrome. <b>2016</b> , 55, 3675-3678		9

139	'Pre-endoscopy point of care test (Simtomax- IgA/IgG-Deamidated Gliadin Peptide) for coeliac disease in iron deficiency anaemia: diagnostic accuracy and a cost saving economic model'. <i>BMC Gastroenterology</i> , <b>2016</b> , 16, 115	3	14
138	Złakie [Das Chamleon der Gastroenterologie. <b>2016</b> , 13, 51-58		
137	Olmesartan-Induced Enteropathy. <b>2016</b> , 12, 230-232		15
136	Olmesartan-Induced Enteropathy: An Unusual Cause of Villous Atrophy. <b>2016</b> , 23, 91-95		10
135	Classification chaos in coeliac disease: Does it really matter?. <b>2016</b> , 212, 1174-1178		4
134	Olmesartan-induced enteropathy associated with cutaneous lesions. <b>2016</b> , 4, 379-82		9
133	Unusual Severe Side Effect of a Commonly Used Drug. <b>2016</b> , 18, 363		1
132	Seronegative celiac disease: Shedding light on an obscure clinical entity. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 1018-22	3.3	54
131	Enteropathy Associated with Olmesartan. <b>2016</b> , 23, 96-100		7
130	Olmesartan-Induced Sprue Like Enteropathy. <b>2016</b> , 23, 101-105		8
129	Sprue-Like Enteropathy Associated With Olmesartan: A New Kid on the Enteropathy Block. <b>2016</b> , 23, 61-65		12
128	Olmesartan-associated sprue-like enteropathy: a systematic review with emphasis on histopathology. <i>Human Pathology</i> , <b>2016</b> , 50, 127-34	3.7	91
127	An emerging issue in differential diagnosis of diarrhea: sprue-like enteropathy associated with olmesartan. <i>Scandinavian Journal of Gastroenterology</i> , <b>2016</b> , 51, 378-80	2.4	6
126	Potential coeliac disease markers and autoimmunity in olmesartan induced enteropathy: A population-based study. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 154-61	3.3	20
125	Severe intestinal malabsorption associated with olmesartan: a French nationwide observational cohort study. <b>2016</b> , 65, 1664-9		65
124	Olmesartan-associated enteropathy: new insights on the natural history? Report of two cases. <i>Scandinavian Journal of Gastroenterology</i> , <b>2016</b> , 51, 152-6	2.4	11
123	[Enteropathy due to olmesartan]. <b>2016</b> , 65, 95-8		1
122	[Sprue-like enteropathy in the elderly treated with olmesartan]. <b>2017</b> , 52, 223-224		1

121	Immunologic Effects of the Renin-Angiotensin System. <b>2017</b> , 28, 1350-1361		80
120	Autoimmune-like chronic hepatitis induced by olmesartan. <b>2017</b> , 66, 2086-2088		7
119	Celiac disease and other intraepithelial lymphocytic disorders of the upper gastrointestinal tract. <b>2017</b> , 23, 62-72		1
118	Performing routine follow-up biopsy 1 year after diagnosis does not affect long-term outcomes in coeliac disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 45, 1459-1468	6.1	18
117	Management of Hypertension Using Olmesartan Alone or in Combination. <b>2017</b> , 6, 13-32		6
116	Small bowel villous atrophy: celiac disease and beyond. <b>2017</b> , 11, 125-138		15
115	Unspecified intestinal malabsorption in patients treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers: a retrospective analysis in primary care settings. <b>2017</b> , 16, 1221-1225		4
114	Letter: sprue-like enteropathy associated with angiotensin II receptor blockers other than olmesartan. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 471-473	6.1	13
113	Letter: sprue-like enteropathy associated with angiotensin II receptor blockers other than olmesartan-authors'reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 473-474	6.1	
112	Clinical and Histologic Mimickers of Celiac Disease. <b>2017</b> , 8, e114		32
111	A Pitfall in Suspected (refractory) Celiac Disease: Losartan-Induced Enteropathy. <b>2017</b> , 112, 1754-1755		5
110	The Many Faces of Medication-Related Injury in the Gastrointestinal Tract. <b>2017</b> , 10, 887-908		8
109	Population Pharmacokinetic Modeling of Olmesartan, the Active Metabolite of Olmesartan Medoxomil, in Patients with Hypertension. <b>2017</b> , 42, 573-581		6
108	Telmisartan-induced sprue-like enteropathy: a case report and a review of patients using non-olmesartan angiotensin receptor blockers. <b>2017</b> , 15, 419-421		10
107	Olmesartan-associated enteropathy. <b>2017</b> , 30, 348-350		9
106	Sprue-like enteropathy, do not forget olmesartan!. <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 621-624	3.3	4
105	Use of olmesartan and enteropathy outcomes: a multi-database study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 792-800	6.1	14
104	Sprue-like enteropathy associated with valsartan. <b>2018</b> , 150, 329		2

103	Collagenous Enteritis is Unlikely a Form of Aggressive Celiac Disease Despite Sharing HLA-DQ2/DQ8 Genotypes. <b>2018</b> , 42, 545-552		30
102	Severe intestinal malabsorption associated with ACE inhibitor or angiotensin receptor blocker treatment. An observational cohort study in Germany and Italy. <b>2018</b> , 27, 581-586		14
101	Sprue-like enteropathy associated with valsartan. <b>2018</b> , 150, 329		
100	Regional Patterns of Olmesartan Prescription and the Prevalence of Duodenal Villous Atrophy Throughout the United States. <b>2018</b> , 16, 584-585		2
99	Autoimmune enteropathies. <b>2018</b> , 472, 55-66		25
98	Angiotensin receptor blocker use and gastro-oesophageal cancer survival: a population-based cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 279-288	6.1	20
97	Celiac Disease and Other Causes of Duodenitis. <b>2018</b> , 142, 35-43		16
96	Olmesartan-associated severe gastritis and enteropathy. <i>BMJ Case Reports</i> , <b>2018</b> , 11,	0.9	6
95	Olmesartan-induced enteropathy. <i>BMJ Case Reports</i> , <b>2018</b> , 2018,	0.9	3
94	Nivolumab-induced celiac-like enteropathy in patient with metastatic renal cell carcinoma: Case report and review of the literature. <b>2019</b> , 7, 1689-1693		6
93	Association of sprue-like enteropathy and angiotensin receptor-1 antagonists. <b>2019</b> , 131, 493-501		3
92	Significant Weight Loss in a Patient Taking Olmesartan: An Unusual Case Report. <b>2019</b> , 14, 238-241		0
91	Angiotensin II receptor blockers and gastrointestinal adverse events of resembling sprue-like enteropathy: a systematic review. <b>2019</b> , 7, 162-167		19
90	Malabsorption and Malnutrition Disorders. <b>2019</b> , 191-238		1
89	Olmesartan Associated Enteropathy: A Rare Underdiagnosed Cause of Diarrhea and Weight Loss. <b>2019</b> , 20, 111-116		11
88	Effects of Drugs and Excipients on Hydration Status. <b>2019</b> , 11,		9
87	[An unusual case of olmesartan induced enteropathy]. <b>2019</b> , 39, 237-240		1
86	Overview in the clinical management of patients with seronegative villous atrophy. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2019</b> , 31, 409-417	2.2	18

85	Celiac Disease: Updates on Pathology and Differential Diagnosis. <b>2019</b> , 26, 292-312	5
84	[Olmesartan therapy and enteropathy: About two cases and review of the literature]. <b>2019</b> , 40, 112-116	1
83	Biopsy Diagnosis of Celiac Disease: The Pathologist's Perspective in Light of Recent Advances. <b>2019</b> , 48, 39-51	13
82	A simple treatment for a potentially life-threatening cause of malabsorption. <b>2019</b> , 14, 967-971	1
81	Telmisartan-induced sprue-like enteropathy: a case report. <b>2020</b> , 27, 49-51	3
80	Olmesartan Associated Enteropathy: Usefulness of Video Capsule Endoscopy in a Case With Doubtful Upper Endoscopic/Histological Picture. <b>2020</b> , 15, 65-68	2
79	Clinical phenotype and mortality in patients with idiopathic small bowel villous atrophy: a dual-centre international study. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2020</b> , 32, 938-949 <sup>2,2</sup>	7
78	Minimal Lesions of the Small Intestinal Mucosa: More than Morphology. <b>2020</b> , 65, 2761-2768	1
77	Inflammatory bowel disease-like conditions: medication-induced enteropathy. <b>2020</b> , 451-469	
76	Preface. <b>2020</b> , ix-ix	
75	The Value of Gastrointestinal Biopsy. <b>2020</b> , 1-12	
74	Gastrointestinal Involvement by Systemic Disease. <b>2020</b> , 13-29	
73	Radiation and the Gastrointestinal Tract. <b>2020</b> , 30-51	
72	Transplantation, Immunodeficiency, and Immunosuppression. <b>2020</b> , 52-64	
71	Gastrointestinal Ischemia and Vascular Disorders. <b>2020</b> , 84-101	
70	Paediatric Conditions. <b>2020</b> , 102-115	
69	Gastrointestinal Dysplasia. <b>2020</b> , 116-130	
68	Histology of Gastroesophageal Reflux Disease and Barrett's Oesophagus. <b>2020</b> , 157-167	

67	Infections of the Oesophagus and Rare Forms of Oesophagitis. <b>2020</b> , 168-178		
66	Assessment of Gastric Biopsies. <b>2020</b> , 179-185		
65	Types of Gastritis. <b>2020</b> , 186-205		
64	Coeliac Disease. <b>2020</b> , 215-235		
63	Inflammatory Bowel Disease and the Upper Gastrointestinal Tract. <b>2020</b> , 236-244		
62	Normal Lower Gastrointestinal Mucosa. <b>2020</b> , 245-259		
61	Infectious Disorders of the Lower Gastrointestinal Tract. <b>2020</b> , 260-286		
60	Jejunitis and Ileitis. <b>2020</b> , 287-309		
59	Microscopic Colitis. <b>2020</b> , 310-324		1
58	Mimics of Inflammatory Bowel Disease. <b>2020</b> , 357-387		0
57	Pharmacy and therapeutics committees strategy to address olmesartan safety issues at a primary care level. <b>2020</b> , 42, 737-743		
56	Olmesartan enteropathy: an important cause of malabsorption and diarrhoea. <i>Internal Medicine Journal</i> , <b>2020</b> , 50, 130-132	1.6	3
55	Syndrom de malabsorci3 intestinal. <i>Medicine</i> , <b>2020</b> , 13, 1-8	0.1	
54	Olmesartan-associated enteropathy: Belgian survey. <i>Therapie</i> , <b>2021</b> , 76, 58-60	3.8	0
53	Severe cases of sprue-like enteropathy associated with angiotensin receptor blockers other than olmesartan. <i>GastroHep</i> , <b>2021</b> , 3, 88-99	1	0
52	Seronegative Celiac Disease; Frequently Encountered Yet Undiagnosed Clinical Entity. <i>Middle East Journal of Digestive Diseases</i> , <b>2021</b> , 13, 35-42	1.1	0
51	Immune-mediated enteropathies: From bench to bedside. <i>Journal of Autoimmunity</i> , <b>2021</b> , 118, 102609	15.5	5
50	Diagnostic and therapeutic challenge of unclassifiable enteropathies with increased intraepithelial CD103 CD8 T lymphocytes: a single center case series. <i>Scandinavian Journal of Gastroenterology</i> , <b>2021</b> , 56, 889-898	2.4	1

49	"Weight Loss Syndrome": A Case of Olmesartan-Associated Enteropathy. <i>Journal of Pharmacy Practice</i> , <b>2021</b> , 8971900211028203	1.3	
48	Coeliac disease enteropathy and symptoms may be aggravated by angiotensin receptor blockers in patients on a gluten-free diet. <i>United European Gastroenterology Journal</i> , <b>2021</b> , 9, 973-979	5.3	1
47	IBD-like gastrointestinal disorders in children. <i>Eksperimentalnaya I Klinicheskaya Gastroenterologiya</i> , <b>2021</b> , 161-169	0.4	1
46	An unusual cause of diarrhoea: case report and literature review of olmesartan-associated enteropathy. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2021</b> ,	2.2	1
45	70-year-old woman with chronic diarrhea. <i>Revista Clínica Española</i> , <b>2021</b> , 221, 411-417	0.5	1
44	Mujer de 70 años con diarrea crónica. <i>Revista Clínica Española</i> , <b>2021</b> , 221, 411-417	0.7	1
43	Severe spruelike enteropathy and collagenous colitis caused by olmesartan. <i>BMC Gastroenterology</i> , <b>2021</b> , 21, 350	3	1
42	Olmesartan-associated sprue-like enteropathy diagnosed by capsule endoscopy and double balloon endoscopy. <i>Clinical Journal of Gastroenterology</i> , <b>2021</b> , 14, 1649-1654	1.1	1
41	Clinical and gastro-duodenal histopathological features of enteropathy due to angiotensin II receptor blockers. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 1262-1267	3.3	3
40	Histopathologic aspects of gluten-related disorders. <b>2022</b> , 113-128		
39	Sprue-Like Enteropathy and Liver Injury: A Rare Emerging Association with Olmesartan. <i>Journal of Investigative Medicine High Impact Case Reports</i> , <b>2021</b> , 9, 23247096211037463	1.2	2
38	Olmesartan-associated duodenal villous atrophy, an emerging clinical issue. <i>Internal Medicine Journal</i> , <b>2020</b> , 50, 624-626	1.6	2
37	An atypical case of chronic diarrhoea: olmesartan-induced sprue-like enteropathy. <i>BMJ Case Reports</i> , <b>2015</b> , 2015,	0.9	7
36	Olmesartan-Associated Enteropathy: An Unexpected Cause of Chronic Diarrhoea. <i>European Journal of Case Reports in Internal Medicine</i> , <b>2019</b> , 6, 001093	1.2	4
35	A Case of Severe Sprue-Like Enteropathy Associated With Valsartan. <i>ACG Case Reports Journal</i> , <b>2015</b> , 2, 92-4	0.6	39
34	A Case of Moderate Sprue-Like Enteropathy Associated With Telmisartan. <i>Journal of Clinical Medicine Research</i> , <b>2017</b> , 9, 1022-1025	2.9	15
33	Clinical, laboratory, serological, and histological profile of sprue-like enteropathy associated with olmesartan use. <i>Revista Española De Enfermedades Digestivas</i> , <b>2016</b> , 108, 685-686	0.9	11
32	Olmesartan is not associated with the risk of enteropathy: a Korean nationwide observational cohort study. <i>Korean Journal of Internal Medicine</i> , <b>2019</b> , 34, 90-98	2.5	7



31	Olmesartan-Induced Spruelike Enteropathy: An Emerging Cause of Small Bowel Injury. <i>Cureus</i> , <b>2020</b> , 12, e9347	1.2	2
30	Sprue-like enteropathy linked to olmesartan. <i>Revista Espanola De Enfermedades Digestivas</i> , <b>2016</b> , 108, 292-3	0.9	3
29	Olmesartan Enteropathy. <b>2016</b> , 232-233		
28	Autoimmune Enteropathy. <b>2016</b> , 234-237		
27	Rare Case of Olmesartan Induced Enteropathy. <i>Spartan Medical Research Journal</i> , <b>2017</b> , 2, 6383	0.3	
26	Severe Sprue-Like Enteropathy and Colitis due to Olmesartan: Lessons Learned From a Rare Entity. <i>Gastroenterology Research</i> , <b>2020</b> , 13, 150-154	1.8	2
25	Clinical factors related to severe enterocolitis after adjuvant CAPOX for colorectal cancer: a retrospective analysis. <i>Ecancermedicalscience</i> , <b>2020</b> , 14, 1014	2.7	1
24	Non-Neoplastic Pathology of the Gastrointestinal Tract: A Practical Guide to Biopsy Diagnosis. <b>2020</b>		
23	Non-Neoplastic Diseases of the Anal Canal. <b>2020</b> , 434-445		
22	Normal Oesophageal, Gastric and Duodenal Mucosa. <b>2020</b> , 131-156		
21	Seronegative villous atrophy. <b>2022</b> , 69-87		
20	Approach to Reporting Inflammatory Bowel Disease Biopsies. <b>2020</b> , 401-409		0
19	Ileal Pouch Anal Anastomosis. <b>2020</b> , 410-416		
18	Diverticular Disease, Mucosal Prolapse, and Related Conditions. <b>2020</b> , 417-433		
17	Drug-Induced Gastrointestinal Disease. <b>2020</b> , 65-83		
16	Duodenitis. <b>2020</b> , 206-214		
15	Inflammatory Bowel Disease Diagnosis. <b>2020</b> , 325-356		1
14	Index. <b>2020</b> , 446-462		

- 13 Complications of Inflammatory Bowel Disease. **2020**, 388-400
- 12 Olmesartan-associated Enteropathy with Acute Kidney Injury.. *Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The*, **2022**, 79, 130-134 0.6 0
- 11 Mosaic theory revised: inflammation and salt play central roles in arterial hypertension.. **2022**, 1
- 10 Drug Induced Digestive tract Injury: Decoding some invisible offenders. *Human Pathology*, **2022**, 3.7 0
- 9 Case report: Confirming a diagnosis of severe olmesartan-associated enteropathy\*. *Therapie*, **2022**, 3.8
- 8 Series: Diagnosis at a Glance. *The Journal of the Japanese Society of Internal Medicine*, **2021**, 110, 1509-1512
- 7 The histological spectrum of ARB-induced gastritis.
- 6 Enteropatía por olmesartán y otros ARA-II. **2022**, 0
- 5 Diseases of the Small Intestine and Colorectum. **2021**, 173-331 0
- 4 Pathologie inflammatoire du tube digestif en 2023 : point de vue du clinicien. **2022**, 0
- 3 Olmesartan-associated sprue-like enteropathy. **2022**, 15, e254189 0
- 2 Candesartan-Induced Enteropathy That Mimics Celiac Disease in a 90-Year-Old Patient. 178-184 0
- 1 Olmesartan and other ARBs induced enteropathy. **2023**, 160, 183-184 0